$ALMR

Pacific Biosciences (PACB), Fortrea (FTRE), Alamar (ALMR), 10x Genomics (TXG), and Azenta (AZTA) reached 52-week highs on October 6, 2026. PACB announced a collaboration with TychoBio, FTRE reported Q2 revenue of $678M, ALMR saw Q2 revenue surge to $29.43M, TXG launched the Atera platform, and AZTA reported 12% Q3 revenue growth.

Alamar Biosciences (ALMR) appointed Bob Ragusa, former CEO of GRAIL, to its board. The company also added John Brottem as general counsel and Amelia Merrill as Chief People Officer. Ragusa's experience in genomics and diagnostics is expected to aid Alamar's mission in early disease detection using its NULISA platform.

Alamar Biosciences (ALMR) stock rose 10.3% to $38.44 in pre-market trading after reporting Q2 2026 revenue growth of 82% YoY to $29.4M and raising full-year revenue guidance to $116M-$120M. Analysts increased price targets, and the company expanded a partnership with the Alzheimer’s Disease Data Initiative.

Alamar Biosciences (ALMR) stock rose 6.8% to $34.20 in morning trading, continuing a rally since its Q2 2026 earnings report showed 82% revenue growth and a 60% gross margin. Analysts raised price targets (JPMorgan to $35, Stifel to $32, BofA to $31), maintaining Buy ratings. The company's Alzheimer’s Disease Data Initiative partnership also boosted investor interest. The broader market had minimal impact, suggesting the gains are specific to ALMR's strong fundamentals and growth prospects.

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, the board of directors (the “Board”) of Alamar Biosciences, Inc. (the “Company”) appointed Robert Ragus

Alamar Biosciences (ALMR) reported Q2 2026 revenue of $29.4M, up 82% YoY, with gross margin at 60%. Consumables rose 147% to $15.5M and instrument revenue rose 35% to $7.8M. Net loss was $13.2M. Cash was $256.3M. Full-year 2026 revenue guidance is $116M to $120M and management targets 100+ new instruments.

Investing.com reports major U.S. stock movers, led by FRMI up 22.2% on an AI campus lease and potential revenue expansion, ALMR up 28.3% after launching an immune profiling panel, and Hertz up 24.5% on index removal and heavy options activity. Other gainers include Septerna, Rapid7, Kopin, and NextNav, with catalysts tied to AI, biotech, and earnings.

Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance FREMONT, Calif.--August 10, 2026 (GLOBE NEWSWIRE)—Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detectio

Alamar Biosciences (Nasdaq: ALMR) announced the launch of its NULISAseq Immune 340 Panel, expanding its NULISAseq Inflammation Panel 250 to measure about 340 immune-related proteins from a single sample. The company says the panel targets low-abundance proteins and regulatory markers, supporting translational research and drug development across cancer, cardiovascular, metabolic, autoimmune, and aging.